AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 7 - (NewsRx.com & NewsRx.net) -- Researchers have identified tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells.
"Thirty HLA-A2+ women with metastatic breast cancer received up to 14 vaccinations with MDA-MB-231-CD80, an HLA-A2+ allogeneic breast cancer cell line, which had been lipofected with the cDNA for the CD80 costimulatory molecule. Tumor cells were administered with BCG or GM-CSF as an adjuvant. Sera obtained before and after vaccination were analyzed for antibodies to tumor cell lysate, MUC1, HER2/neu and p53," scientists in the United States and the Netherlands report.
"Since the cell line was grown in fetal bovine serum (FBS), sera were also analyzed for antibodies to FBS," stated Annemieke Dols and colleagues at the Earle A. Chiles Research Institute in Portland, Oregon, the University of Washington in Seattle, and the Vrije Universiteit Medisch Centrum in the Netherlands. "Eighteen of 24 patients for whom sera were available exhibited anti-FBS activity at baseline. Eleven of these 18 patients and all six patients without baseline anti-FBS activity showed an increased titer after vaccination. The anti-FBS activity required that serum samples be absorbed in excess FBS to detect specific antibodies to tumor cell lysate.
"A two-fold increase in the titer of IgG specific to tumor ...